Insider Buying: NewAmsterdam Pharma (NASDAQ:NAMS) Director Acquires $84,185.10 in Stock

NewAmsterdam Pharma (NASDAQ:NAMS) Director James N. Topper bought 4,005 shares of the company’s stock in a transaction dated Tuesday, March 4th. The stock was purchased at an average price of $21.02 per share, with a total value of $84,185.10. Following the completion of the transaction, the director now directly owns 3,012,434 shares in the company, valued at approximately $63,321,362.68. This represents a 0.13 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

NewAmsterdam Pharma Price Performance

NAMS stock opened at $23.80 on Friday. The company has a 50 day simple moving average of $22.20 and a 200 day simple moving average of $20.51. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of -9.15 and a beta of -0.04. NewAmsterdam Pharma has a 1 year low of $15.19 and a 1 year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.47). The company had revenue of $12.77 million for the quarter, compared to analyst estimates of $3.30 million. On average, equities research analysts anticipate that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its holdings in NewAmsterdam Pharma by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock worth $1,433,000 after acquiring an additional 1,399 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in NewAmsterdam Pharma during the 4th quarter worth approximately $50,000. National Bank of Canada FI bought a new stake in NewAmsterdam Pharma during the 4th quarter worth approximately $51,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in NewAmsterdam Pharma during the 4th quarter worth approximately $80,000. Finally, Legal & General Group Plc grew its holdings in NewAmsterdam Pharma by 24.8% during the 4th quarter. Legal & General Group Plc now owns 22,946 shares of the company’s stock worth $590,000 after acquiring an additional 4,556 shares during the last quarter. 89.89% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Scotiabank boosted their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research report on Thursday, February 27th. Royal Bank of Canada restated an “outperform” rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Needham & Company LLC dropped their target price on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a research report on Thursday, February 27th. Finally, HC Wainwright reiterated a “buy” rating and set a $48.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $43.80.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.